As of the 2025 fiscal year, Saline Nasal Sprays continue to dominate the market in terms of unit volume, accounting for 44% of global sales. With over 320 million units sold annually, saline sprays are the primary choice for pediatric care and daily hygiene due to their drug-free profiles. Pediatricians currently recommend saline formulations in 71% of all infant nasal congestion cases, driving the high-volume growth of private-label variants.

Steroid Nasal Sprays hold the second-largest share at 28%, with approximately 54 million units distributed in 2024–2025. Despite lower unit volumes compared to saline, steroid sprays represent a higher value segment due to their status as the "Gold Standard" for chronic sinusitis and allergic rhinitis. Technical data in the Nasal Spray Market reports show that 78% of clinical trials in 2025 confirm significant inflammation reduction within 14 days, reinforcing physician preference for corticosteroids like Fluticasone and Mometasone.